Boundless Bio Q2 R&D Expenses Down 17%, Cash to Fund Operations Until H1 2028

Boundless Bio (BOLD) reported Q2 R&D expenses of $12.2mln, a 17% drop from the same period in 2024. Cash and investments totaled $127.1mln, expected to fund operations into H1 2028. The biotech company develops targeted cancer therapies based on extrachromosomal DNA biology.

Boundless Bio (NASDAQ: BOLD), a biotechnology company focused on developing targeted cancer therapies based on extrachromosomal DNA (ecDNA) biology, released its second-quarter 2025 financial results. The company reported a significant reduction in research and development (R&D) expenses, with costs dropping to $12.2 million, a 17% decrease from the same period in 2024 [1].

The quarter ended with $127.1 million in cash, cash equivalents, and short-term investments, which management expects to fund operations into the first half of 2028 [1]. This financial position supports the company's ongoing clinical trials and pipeline development.

Boundless Bio's core focus is its Spyglass platform, which identifies drug targets involved in ecDNA function. The company's lead program, BBI-355, targets oncogene amplification through small molecule drugs. Additionally, the company is developing BBI-940, a new oncology drug targeting kinesin, a protein that plays a role in cell division [1].

The company's second-quarter 2025 financial results also include a net loss of $15.7 million, compared to $17.0 million in the same period in 2024. General and administrative expenses were $4.8 million, up slightly from $4.7 million in the same period in 2024 [1].

Looking ahead, investors should monitor progress in the BBI-355/BBI-825 combination trial and the regulatory submission timeline for BBI-940. Success in these programs will drive future updates and may influence funding needs if clinical milestones shift. The company will remain pre-revenue until its drug candidates advance further in clinical development and eventually gain regulatory approval [1].

References:
[1] https://www.nasdaq.com/articles/boundless-bio-bold-q2-rd-drops-17
[2] https://www.morningstar.com/news/globe-newswire/9506127/boundless-bio-reports-second-quarter-2025-financial-results-and-business-highlights